DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/z7ksr6/cellulite) has announced the addition of the "Cellulite - Pipeline Review, H2 2013" report to their offering.
This report provides information on the therapeutic development for Cellulite, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cellulite. Cellulite - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope
- A snapshot of the global therapeutic scenario for Cellulite.
- A review of the Cellulite products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cellulite pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- News and deals relating to the products
Reasons to Buy
- Identify and understand important and diverse types of therapeutics under development for Cellulite.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cellulite pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Companies Mentioned
-
Auxilium Pharmaceuticals
- Easton Pharmaceuticals
- Halozyme Therapeutics
- Helix BioMedix
-
Kedem Pharmaceuticals
For more information visit http://www.researchandmarkets.com/research/z7ksr6/cellulite
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
